Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Clinical Chemistry
Emerging Technology
Immunoassays
Molecular Diagnostics
Pathology & AI
Liquid Biopsy
Illumina unveils new version of liquid biopsy assay
Genomics company Illumina has announced a new generation of its distributed liquid biopsy assay for the genomic profiling of solid tumors.
November 8, 2023
Sophia Genetics, AstraZeneca, Memorial Sloan Kettering to collaborate on cancer test access
Sophia Genetics is collaborating with Memorial Sloan Kettering (MSK) Cancer Center and AstraZeneca to expand MSK's genomic sequencing tests to a global scale, with the aim of by providing more inclusive access to cancer testing worldwide.
October 20, 2023
AMP publishes best-practice recommendations for ctDNA assays
The Association for Molecular Pathology (AMP) has published its best-practice recommendations for validating, reporting, and publishing clinical circulating tumor DNA (ctDNA) assays.
October 17, 2023
Agilent to sell Resolution Bioscience to Exact Sciences
Agilent Technologies has announced that it is selling Resolution Bioscience, its cancer testing business, to Exact Sciences for an undisclosed sum.
September 12, 2023
Agilent closes $550M liquid biopsy unit after failing to find path to profits
When Agilent bought Resolution, it identified the company’s presence in fast-growing NGS technologies for precision oncology as a way to expand its addressable market; rather than realizing that opportunity, Agilent has ended up cutting its losses.
August 18, 2023
Cancer detection firm Elypta awarded quality certification
The scope of the certification includes the design and development of in vitro diagnostic (IVD) test kits and software for Elypta’s liquid biopsy-based platform for the detection and measurement of glycosaminoglycans (GAGomes) across different cancers.
July 7, 2023
Quest Diagnostics completes acquisition of Haystack Oncology, adds MRD liquid biopsy to Dx portfolio
Quest expects next year to use the MRD technology in blood-based clinical lab testing services for solid tumor cancers.
June 21, 2023
Myriad Genetics, MD Anderson collaborate on metastatic renal cell carcinoma research
The project will use Myriad’s minimal residual disease testing platform, a tumor-informed high-definition assay that detects circulating tumor DNA.
June 12, 2023
Foundation Medicine enters companion diagnostic collaboration with Merck KGaA
The agreement builds on a partnership the firms entered in 2020 to accelerate the development of novel targeted therapies.
June 5, 2023
Devyser, Thermo Fisher ink collaboration, distribution agreement
The agreement gives Thermo Fisher Scientific the exclusive rights to commercialize Devyser's post-transplant portfolio of next-generation sequencing products in North America and Europe.
April 24, 2023
Karius, eGenesis to develop infectious disease diagnostic tests for xenotransplantation
Through the partnership, Karius will leverage its testing platform to enable the detection and quantification of pathogens with potential to occur in porcine organ donors.
April 11, 2023
GC Genome liquid biopsy technology in study predicts solid tumor radiation therapy response
The research conducted in collaboration with the Samsung Medical Center, Sungkyunkwan University School of Medicine, used I-score, a tool for calculating genomic instabilities developed by GC Genome.
April 10, 2023
Page 1 of 4
Next Page
